Superior Plus Reports Voting Results of Annual and Special Meeting of Shareholders
TORONTO, May 13, 2025--(BUSINESS WIRE)--Superior Plus Corp. ("Superior Plus" or "the Company") (TSX:SPB) held its annual and special meeting of shareholders on May 13, 2025 virtually (the "Meeting") and is pleased to announce that all resolutions voted upon were approved. Pursuant to the requirements of the Toronto Stock Exchange, Superior is issuing this news release to summarize the voting results in respect of the Meeting.
A total of 134,424,278 shares of the Company ("Shares") comprised of 104,421,441 Common Shares and 30,002,837 Series 1 Special Voting Preferred Shares representing approximately 51.28% of the votes attached to all outstanding Shares, were present or represented by proxy at the Meeting.
Each of the 10 director nominees of the Company listed in the management information circular of the Company dated March 25, 2025 were elected by ordinary resolution passed by a vote of the holders of Shares conducted by ballot at the Meeting as follows:
Nominee
Votes For
Votes Against
Number
Percentage
Number
Percentage
Catherine M. Best
123,988,943
93.53%
8,574,492
6.47%
Jean Paul (J.P.) Gladu
128,970,939
97.29%
3,592,496
2.71%
Patrick E. Gottschalk
127,952,759
96.52%
4,610,676
3.48%
Jennifer M. Grigsby
127,788,890
96.40%
4,774,545
3.60%
Michael J. Horowitz
124,288,719
93.76%
8,274,716
6.24%
Calvin B. Jacober
124,017,671
93.55%
8,545,764
6.45%
Allan A. MacDonald
127,384,946
96.09%
5,178,489
3.91%
Laura L. Schwinn
129,270,531
97.52%
3,292,904
2.48%
David P. Smith
120,413,372
90.83%
12,150,063
9.17%
William T. Yardley
129,090,346
97.38%
3,473,089
2.62%
Shareholders also approved an ordinary resolution appointing Ernst & Young LLP as the Company's auditors (99.38%), approved an ordinary resolution approving a new stock option plan for the Company (93.45%), approved a special resolution reducing the stated capital account maintained in respect of the Common Shares to Cdn$5 per share (99.04%) and approved a non-binding advisory vote regarding the Company's approach to executive compensation (92.09%).
About Superior Plus
Superior Plus is a leading North American distributor of propane, compressed natural gas, renewable energy and related products and services, servicing approximately 750,000 customers in the U.S. and Canada. Through its primary businesses, propane distribution and CNG, RNG and hydrogen distribution, Superior Plus safely delivers low carbon1 fuels to residential, commercial, utility, agricultural and industrial customers not connected to a pipeline. By displacing more carbon intensive fuels, Superior Plus is a leader in the energy transition and helping customers lower operating costs and improve environmental performance.
1 Superior Plus defines 'low carbon' and 'lower carbon' fuels as those with a lower carbon intensity than fossil fuels that may be utilized in the same application (e.g. diesel, gasoline).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513451299/en/
Contacts
FOR MORE INFORMATION
Superior Plus Corp. Website: www.superiorplus.com E-mail: investor-relations@superiorplus.com Toll-Free: 1-866-490-PLUS (7587)
Chris Lichtenheldt, Vice President, Investor RelationsTel: (905) 285-4988
Carolyn Skinner, Senior Manager, Corporate CommunicationsTel: (416) 428-9186
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
MangoBoost Sets New Benchmark for Multi-Node LLM Training on AMD GPUs in MLPerf Training v5.0
BELLEVUE, Wash.--(BUSINESS WIRE)--MangoBoost, a provider of cutting-edge system solutions for maximizing compute efficiency and scalability, has validated the scalability and efficiency of large-scale AI training on AMD Instinct™ MI300X GPUs through its MLPerf Training v5.0 submission. Tailored for enterprise data centers prioritizing performance, flexibility, and cost-efficiency, this milestone demonstrates that state-of-the-art LLM training is now viable beyond traditional vendor-locked GPU platforms. This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC. Share Using 32 AMD Instinct™ MI300X GPUs across four nodes, MangoBoost fine-tuned the Llama2-70B-LoRA model in just 10.91 minutes, setting the fastest multi-node MLPerf benchmark on AMD GPUs to date. The system achieved near-linear scaling efficiency (95–100%), proving that MangoBoost's stack can support practical and scalable LLM training in production environments. Scalability and Efficiency for Enterprise Data Centers The result showcases more than just benchmark success—it underscores how enterprises can reliably scale LLM training across clusters without network bottlenecks or rigid infrastructure dependencies. Mango LLMBoost™: A full-featured MLOps software platform for large language models, supporting model parallelism, automatic tuning, batch scheduling, and advanced memory management. Mango GPUBoost™ RoCEv2 RDMA: Inter-GPU communication hardware optimized for low-latency, high-throughput node-to-node communication, sustaining line-rate performance across thousands of concurrent QPs. These technologies together deliver predictable and efficient multi-node training, ideal for organizations operating their own AI infrastructure or deploying on public cloud. Industry-First MLPerf Training on AMD MI300X GPUs This is the first-ever MLPerf Training submission on AMD GPUs spanning multiple nodes. MangoBoost's platform demonstrated robust performance with a 4-node, 32-GPU cluster and confirmed compatibility with additional model sizes and structures—including Llama2-7B and Llama3.1-8B—in internal benchmarks. These results validate the generalizability of MangoBoost's platform beyond benchmarks to diverse production-scale use cases. " I'm excited to see MangoBoost's first MLPerf Training results, pairing their LLMBoost AI Enterprise MLOps software with their RoCEv2-based GPUBoost DPU hardware to unlock the full power of AMD GPUs, demonstrated by their scalable performance from a single-node MI300X to 2- and 4-node MI300X results on Llama2-70B LoRA. Their results underscore that a well-optimized software stack is critical to fully harness the capabilities of modern AI accelerators." — David Kanter, Founder, Head of MLPerf, MLCommons Vendor-Neutral AI Infrastructure Enabled by AMD Collaboration The achievement was made possible through deep collaboration with AMD and seamless integration with the ROCm™ software ecosystem, enabling full utilization of MI300X's compute, memory bandwidth, and capacity. Enterprises are now empowered to choose infrastructure based on business needs—not vendor constraints. " We congratulate MangoBoost on their MLPerf 5.0 training results on AMD GPUs and are excited to continue our collaboration with them to unleash the full power of AMD GPUs. In this MLPerf Training submission, MangoBoost has achieved a key milestone in demonstrating training results on AMD GPUs across 4 nodes (32 GPUs). This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC." — Meena Arunachalam, Fellow, AI Performance Design Engineering, AMD "At MangoBoost, we've shown that software-hardware co-optimization enables scalable, efficient LLM training without vendor lock-in. Our MLPerf result is a key milestone proving our technology is ready for enterprise-scale AI training with superior efficiency and flexibility," said CEO Jangwoo Kim. MangoBoost continues to develop innovations in communication optimization, hybrid parallelism, topology-aware scheduling, and domain-specific acceleration to further scale performance in distributed AI workloads. About MangoBoost MangoBoost is a provider of cutting-edge, full-stack system solutions for maximizing compute efficiency and scalability. At the heart of the solutions is the MangoBoost Data Processing Unit (DPU), which ensures full compatibility with general-purpose GPUs, accelerators, and storage devices, enabling cost-efficient, standardized AI infrastructure. Founded in 2022 on a decade of research, MangoBoost is rapidly expanding its operations in the U.S., Canada, and Korea.
Yahoo
31 minutes ago
- Yahoo
QPS Celebrates 30th Anniversary
NEWARK, Del., June 04, 2025--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. "30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions," said founder and CEO of QPS, Dr. Benjamin Chien. "Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more," said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email info@ View source version on Contacts QPS CONTACT: Name: Gabrielle PastorePhone: 1-302-635-4290Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Renewal of the drawdown under the Revolving Credit Facility for a six-month period
Press release 4 June 2025Renewal of the drawdown under the Revolving Credit Facility for a six-month periodParis, 4 June 2025 - Clariane ( - ISIN FR0010386334) announces that it has renewed the drawdown of its RCF (Revolving Credit Facility) for a period of 6 months for an amount of €490.8 million, in accordance with the terms of the contract signed February 14th, addition to the usual conditions, the Group points out that the drawdown and renewal of its RCF line are subject to a minimum liquidity level of €300 million on the day of the drawdown or renewal, which includes the RCF drawn down. This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, concerning the Group's future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on 1 April 2025 under registration number D.25-0209, available on the Company's website ( and that of the AMF ( All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane's past performance should not be taken as a guide to future performance. The main Alternative Performance Indicators (APIs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the Company's website at ClarianeClariane is the leading European community of care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain. Relying on their diverse expertise, each year, the Group's 60,000 professionals provide services to 900,000 patients and residents in three main areas of activity: care homes (Korian, Seniors Residencias, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, etc.), and alternative living solutions (Petits-fils, Ages & Vie, etc.). In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: 'taking care of each person's humanity in times of vulnerability'.Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September ticker: - ISIN: Bisseuil Benoît Lesieur Head of Investor Relations Deputy Head of Investor Relations – ESG +33 6 58 60 68 69 +33 6 64 80 15 90 Julie Mary Florian Bachelet Press officer Press officer +33 6 59 72 50 69 +33 6 79 86 78 23 Attachment Press Release Clariane-renewal of drawdown under the RCFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
